Press Release

Synthonics to be Featured on the "Parkinson's Radio Hour"

Dr. Thomas Piccariello will be featured on the May 10th 11AM EST broadcast of the "Parkinson's Radio Hour" on WBZT AM 1230. Dr. Piccariello will discuss Synthonics' lead compound MCP-311 (Bismuth-Subdopate) to treat the symptoms of Parkinson's disease. MCP-311 is formulated with Synthonics' proprietary metal coordination technology that in pre-clinical studies provides a steady release of levodopa beyond 20 hours vs. 3-4 hours with the current therapies. Synthonics is in the process of filing an Investigational New Drug (IND) application to the FDA to perform Phase I human clinical trials with MCP-311 in late 2014.

Read More

Welcome to Synthonics

We are a specialty pharmaceutical company focused on the discovery, development and licensing of drugs that incorporate our proprietary metal coordination chemistry. Metal coordination entails attaching a pharmaceutically acceptable metal, such as zinc, bismuth or magnesium, to a known pharmaceutical agent to create a new and more effective drug. The addition of the metal changes the way the drug is absorbed or delivered without altering the action of the underlying drug.

Metal coordination offers tremendous flexibility, allowing us to "dial in" the desired pharmacokinetics by varying the metals used and the manner in which they are attached. In its simplest application, metal coordination improves a drug's absorption and delivery without changing the way the drug works once delivered. Metal coordination can also be used to extend or control a drug’s release or to prevent a drug's systemic absorption.

Unlike salts, metal coordinated pharmaceuticals are generally patentable as new compositions of matter under U.S. patent laws--even if the parent drug is already well known. We hold four U.S. patents and have dozens of additional claims pending.

Metal coordination is a platform technology with broad application that can be profitably applied both to already marketed drugs and to drugs under development. We have drug discovery and development programs underway on a handful of molecules. In addition, we partner with large pharmaceutical companies to enhance their pipeline and marketed products.

Synthonics, Inc.     2200 Kraft Drive, Suite 2225      Blacksburg, VA 24060     Phone (540) 443-3645